Stupp R et al., 2005-03-10: EORTC-NCIC phase 3 trial in 573 patients with newly diagnosed glioblastoma comparing radiotherapy alone with radiotherapy plus concomitant and adjuvant temozolomide. Median survival 14.6 versus 12.1 months; 2-year survival 26.5% versus 10.4%.
At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone.
p.987 (Abstract, Results)
Stupp R et al., 2005-03-10: EORTC-NCIC phase 3 trial in 573 patients with newly diagnosed glioblastoma comparing radiotherapy alone with radiotherapy plus concomitant and adjuvant temozolomide. Median survival 14.6 versus 12.1 months; 2-year survival 26.5% versus 10.4%. No funding statement in this abstract; the 5-year follow-up (CHD-04) lists Schering-Plough, maker of temozolomide (Temodar), among funders. Comparator: radiotherapy alone. The 2.5-month median gain is small in absolute terms, which is what 'minimal impact' trades on; the doubling of 2-year survival is what cuts against it. Both figures belong together. Study type: randomized trial.
